Farinha Inês, Gibson Peter G, McDonald Vanessa M, Heaney Liam G
Pulmonology Department, Local Health Unit of the Leiria Region, Leiria, Portugal.
Centre of Excellence in Treatable Traits, College of Health, Medicine, and Wellbeing, University of Newcastle, New Lambton Heights, New South Wales, Australia; Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, New South Wales, Australia; Asthma and Breathing Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.
J Allergy Clin Immunol Pract. 2025 Jul;13(7):1542-1552. doi: 10.1016/j.jaip.2025.05.002. Epub 2025 May 8.
In recent years, the significant impact of disease-modifying anti-asthmatic drugs has provided a chance to reevaluate goals in asthma treatment and consider remission as a more ambitious and achievable target. Clinical remission in asthma, both on- and off-treatment, has been characterized by the absence of asthma-related symptoms, attacks, and systemic corticosteroids, and the improvement or stabilization of lung function, all maintained over a minimum of 12 months. Targeting treatable traits has emerged as a promising strategy for the personalized treatment of chronic airway diseases in both primary and specialist care. This multidimensional approach involves the initial identification and tailored treatment of clinically essential characteristics in individual patients, called super-traits. Considering the heterogeneous and multifaceted nature of asthma and associated comorbidities, the novelty of this review is the proposal to use pulmonary, extrapulmonary, and behavioral treatable traits as a tool to reach remission.
近年来,疾病修饰抗哮喘药物的显著影响为重新评估哮喘治疗目标以及将缓解视为更具雄心且可实现的目标提供了契机。哮喘的临床缓解,无论在治疗期间还是治疗后,其特征均为无哮喘相关症状、发作以及全身使用糖皮质激素,且肺功能得到改善或稳定,所有这些均持续至少12个月。针对可治疗特征已成为在初级和专科护理中对慢性气道疾病进行个性化治疗的一种有前景的策略。这种多维度方法涉及最初识别个体患者临床上的关键特征(即超级特征)并进行针对性治疗。鉴于哮喘及相关合并症的异质性和多面性,本综述的新颖之处在于提议将肺部、肺外及行为方面的可治疗特征作为实现缓解的工具。